Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (symbol: ATXS) is a pioneering biopharmaceutical company dedicated to developing transformative treatments for rare and niche allergic and immunological diseases. With a mission to improve the lives of patients and families impacted by these conditions, Astria Therapeutics is at the forefront of innovative medical research and development.
The company’s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein. This promising therapy is currently in preclinical development, targeting the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and severe swelling. By inhibiting plasma kallikrein, STAR-0215 aims to prevent the debilitating effects of HAE, offering hope to patients worldwide.
Astria Therapeutics is also advancing another significant product candidate, STAR-0310. This monoclonal antibody OX40 antagonist is being developed to treat atopic dermatitis (AD), an immune disorder that causes chronic skin inflammation and intense itching. Currently in preclinical development, STAR-0310 targets the immune pathways involved in AD, potentially providing relief and improved quality of life for sufferers.
Recently, Astria Therapeutics has made significant strides in its research and development efforts. The company remains committed to advancing its pipeline and exploring strategic partnerships to bring these innovative therapies to market. Financially, Astria Therapeutics continues to focus on maintaining a strong balance sheet to support its ambitious research programs and clinical trials.
In addition to its core projects, Astria Therapeutics actively engages with the medical community, patient advocacy groups, and regulatory bodies to ensure its treatments meet the highest standards of efficacy and safety. By fostering these collaborations, the company aims to accelerate the delivery of breakthrough therapies to those in need.
For the latest updates on Astria Therapeutics, including news on their clinical trials, partnerships, and corporate developments, stay tuned to StockTitan.
Astria Therapeutics (Nasdaq: ATXS) announced the grant of stock options for 123,500 shares of its common stock on July 1, 2024, under its 2022 Inducement Stock Incentive Plan.
This grant, aimed at three new employees, aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for their employment.
Each option has an exercise price of $9.25, equal to the closing price on the grant date, and will vest over four years.
25% of the shares will vest after the first year of employment, with the remainder vesting monthly over the next three years, contingent on continued employment.
Astria Therapeutics announced on June 3, 2024, that it has granted stock options to purchase 40,000 shares of common stock under its 2022 Inducement Stock Incentive Plan. These options were provided as an inducement to a new employee, with the exercise price set at $9.16, matching the closing price of the stock on the grant date. The vesting schedule spans four years: 25% on the first anniversary of the employee's start date and the remaining shares vesting monthly over the next 36 months. The grants comply with Nasdaq Listing Rule 5635(c)(4).
Astria Therapeutics (NASDAQ: ATXS), a biopharmaceutical company specializing in therapies for allergic and immunological conditions, announced that CEO Jill C. Milne, Ph.D., will participate in a fireside chat at the Jefferies Healthcare Conference. The event is scheduled for June 6th at 10:00am ET in New York, NY. A webcast of the presentation will be available live and as an archived replay for 30 days on the company's investor relations website.
Astria Therapeutics (NASDAQ: ATXS) will present final Phase 1a data for STAR-0215 at the Eastern Allergy Conference in Palm Beach, Florida, on June 1, 2024. The focus will be on updated results for hereditary angioedema treatment. Jessica Best, VP of Medical Affairs, will present the poster at 9:45am EST.
Astria Therapeutics (NASDAQ: ATXS) will present two posters at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, on June 1, 2024.
Dr. Marcus Maurer will present the ALPHA-SOLAR trial of STAR-0215 for treating hereditary angioedema (HAE), detailing its rationale and design.
Dr. Nikos Biris will present on the characterization of STAR-0310, a novel OX40 antagonistic monoclonal antibody.
Both sessions will take place on June 1 at 12:00pm CEST.
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported financial results for Q1 2024, highlighting the positive proof-of-concept results of STAR-0215 for HAE treatment. The company plans to start Phase 3 trials in Q1 2025 and expand label with Q6M administration. Moreover, Astria is developing STAR-0310 for atopic dermatitis and aims to submit an IND application by 2024. The company also shared corporate updates and financial results.
Astria Therapeutics, a biopharmaceutical company, will be presenting information on STAR-0310 at the Society for Investigative Dermatology Annual Meeting. The presentation will focus on the preclinical profile of a novel OX40 antagonistic monoclonal antibody. Dr. Chunxia Lily Zhao will present the poster at the event in May 2024.
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 173,500 shares of common stock under the 2022 Inducement Stock Incentive Plan to new employees. The options have an exercise price of $9.50, vesting over four years, with 25% vesting after one year and the rest monthly over 36 months, contingent on continued employment.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
What does Astria Therapeutics, Inc. specialize in?
What is STAR-0215?
What is hereditary angioedema (HAE)?
What is STAR-0310?
What is atopic dermatitis (AD)?
How is Astria Therapeutics funded?
Does Astria Therapeutics collaborate with other organizations?
How can I stay updated on Astria Therapeutics' latest developments?
What is the significance of STAR-0215 in treating HAE?
What are the benefits of STAR-0310 for atopic dermatitis patients?
